

Supplementary Table 2. Overview of the study characteristics and reported prevalence of CAA pathology in cognitively normal elderly

Author	Year	Country	Area	Definition domain	Study acronym/ name of cohort	n	Age: mean (SD) or median (range)	Female (%)	Hypertension (%)	Prevalence CAA pathology: overall (mild/moderate/ severe/moderate-to- severe) (%)	QA
Alakbarzade ²⁶	2021	UK	West	Cases without significant neurodegenerative pathology	Dementia Research network	25	82 (10.2)	40.0	NR	40 (NR/NR/NR/NR)	2.5
Bergeron ²⁷	1987	Canada	West	Clinically non-demented, age-matched	Toronto University Hospital	30	68 (9.8)	NR	NR	40 (17/13/10/23)	3.5
Bertrand ²⁸	2008	Poland	West	No neurodegenerative or psychiatric disease, no dementia, age-matched	Institute of Psychiatry and Neurology, Warsaw	14	74.96 (9.8)	50.0	NR	29 (14/14/0/14)	1.5
Brayne ²⁹	2009	UK	West	Clinically non-demented	CC75C	100	90.7 (4.5)	61.0	NR	30 (26/3/1/4)	2
Chalmers ³⁰	2003	UK	West	No AD pathological change	SWBB	53	75 (8.3)	45.3	NR	36 (26/6/4/9)	3
Cholerton ⁴	2013	USA	West	CASI >86	ACT	196	86 (7.2)	52.0	NR	21 (12/8/1/9)	4.5
Cruz-Sánchez ³¹	2000	Spain	West	No neurological disease	NR	38	67 (18)	34.2	NR	18 (NR/NR/NR/NR)	7
Daillaire-Théroux ³²	2022	Canada	West	Cognitively intact adults. n=9 for each of the following age groups: 50–59, 60–69, 70–79, 80–89	Centre Hospitalier Universitaire de Québec histological archives	36	69.2	47.2	NR	31 (NR/NR/NR/NR)	6.5
Davis ³³	1999	USA	West	Cognitively and neurologically normal	Kentucky University Hospital	59	83.9 (7.4)	52.5	25.4	76 (NR/NR/NR/NR)	1
De Reuck ³⁴	2013	France	West	Death not related to brain disease	NR	14	74*	64.3	NR	NR (NR/NR/7/NR)	4
De Reuck ³⁵	2019	France	West	No neurological disease/cognitive decline/stroke	Lille University Hospital	20	66 (12)	40.0	NR	0 (0/0/0/0)	4.5
Dickson ³⁶	1992	USA	West	Non-demented	Bronx Aging Study	14	89	71.4	NR	36 (NR/NR/NR/NR)	5.5
Dugger ³⁷	2014	USA	West	No clinico-neuropathological diagnosis	AZSAND, BSHRI, BBDP	166	83 (9.3)	44.0	NR	20 (NR/NR/NR/NR)	6.5
Erten-Lyons ⁶	2013	USA	West	No cognitive impairment or dementia, CDR=0	Oregon Brain Aging Study	27	92.1 (5.1)	55.6	NR	41 (NR/NR/NR/NR)	5.5
Esiri ³⁸	2015	UK	West	No AD (CERAD criteria), Braak stage ≤2	OPTIMA	70	82.6 (7.7)	44.3	74.3	51 (NR/NR/0/NR)	4
Esiri ³⁹	1986	UK	West	No clinicopathological evidence for dementia/CNS disease	Radcliffe Infirmary, Oxford	26	81	NR	NR	27 (NR/NR/0/NR)	10.5
Guidoux ⁴⁰	2018	France	West	Non-neurologic patients, age- and sex matched	Hospices Civils de Strasbourg	59	76 (70–91)*	49.2	33.9	15 (NR/NR/NR/NR)	5.5
Haglund ⁴¹	2002	Sweden	West	Non-demented, no AE/ neurodegenerative or vascular pathology	LLDS	10	79	NR	NR	20 (NR/NR/NR/NR)	4
Head ⁴²	2017	USA	West	Non-demented	UCI ADRC	37	80.3 (10.0)	40.5	NR	19 (11/8/0/8)	7
Honig ⁴³	2005	USA	West	Clinically non-demented	NACC (1985–2003)	225	82.9 (10)	56.4	NR	45 (NR/NR/NR/NR)	7.5
Jellinger ⁴⁴	2010	Austria	West	Pathologically and clinically non-demented, age-matched	Institute of Clinical Neurobiology, Vienna	486	79 (7.6)	54.9	NR	30 (NR/NR/20/NR)	3

Supplementary Table 2. Continued

Author	Year	Country	Area	Definition domain	Study acronym/ name of cohort	n	Age: mean (SD) or median (range)	Female (%)	Hypertension (%)	Prevalence CAA pathology: overall (mild/moderate/ severe/moderate-to- severe) (%)	QA
Kawas ⁴⁵	2015	USA	West	90+ elderly without dementia	90+ study	85	97.5	63.5	NR	9 (NR/NR/NR/NR)	7.5
Kövari ¹²	2013	Switzerland	West	Non-demented	University Hospitals Geneva 2007	59	75.6 (11.1)	49.2	NR	46 (NR/NR/NR/NR)	2
Love ⁴⁶	2003	UK	West	Neurologically normal, no pathological evidence of AD (CERAD)	Frenchay Hospital, Bristol	152	(60–102)*	48.7	NR	32 (NR/NR/NR/NR)	4
Magaki ⁴⁷	2014	USA	West	Non-demented	UCLA	124	70.7 (8.2)	41.1	NR	0 (0/0/0/0)	7
Malek-Ahmadi ⁴⁸	2019	USA	West	Elderly non-demented individuals	Rush Religious Order Study	98	NR	NR	NR	71 (NR/NR/NR/NR)	6
Matthews ¹⁵	2009	UK	West	Clinically non-demented	MRC CFAS	178	NR	NR	NR	27 (17/10/0/10)	8
McAleese ⁴⁹	2019	UK	West	Non-cognitively impaired, with at least 1 deep WMH	Institute of Neuroscience, Newcastle	22	84.4 (8.6)	50.0	NR	36 (23/9/5/14)	3.5
McKee ⁵⁰	2006	USA	West	Cognitively intact, CDR=0	FHS	25	81.5 (15)	48.0	NR	60 (32/12/16/28)	3
Mountjoy ⁵¹	1982	UK	West	Patients who died whilst under general medical/psychiatric care, no dementia	Newcastle General Hospital	30	76	50.0	NR	40 (NR/NR/NR/NR)	5
Premkumar ⁵²	1996	USA	West	No clinical or histopathological evidence of AD	CWRU	16	70	43.8	NR	0 (0/0/0/0)	6
Robinson ²⁰	2018	UK	West	Clinically cognitively unimpaired	UMLS CNHOA	57	89*	64.9	NR	NR (NR/NR/NR/16)	2.5
Shim ⁵³	2015	USA	West	Clinically healthy, cognitively normal	CCCVd	14	90.9 (6.0)	64.3	42.9	79 (NR/NR/NR/NR)	4
Sugarman ⁵⁴	2019	USA	West	Elderly with normal cognition	NACC-UDS and NACC-NDS	417	NR	NR	NR	17 (NR/NR/NR/NR)	10.5
Wu ⁵⁵	1992	USA	West	Clinically non-demented, age-matched	Albert Einstein College of Medicine, New York	34	79.1 (10.1)	70.6	NR	50 (44/3/3/6)	6.5
Xu ⁵⁶	2004	China	East Asia	No clinical or pathological involvement of CNS	PLA General Hospital, Beijing	28	65.8 (22.8)	17.9	NR	25 (NR/NR/NR/NR)	4
Yamada ⁵⁷	2002	Japan	East Asia	No AD/ neurodegenerative disease	Kanazawa University Hospital	119	85.7 (8)	NR	NR	35 (NR/NR/NR/NR)	3

Prevalence of CAA pathology shows the overall prevalence (irrespective of CAA grade), and, if reported, the prevalence of different stages of CAA (mild, moderate, severe, or moderate-to-severe).

ACT, Adult Changes in Thought cohort; AZSAND, Arizona Study of Aging and Neurodegenerative Disorders; BBDP, Brain and Body Donation Program; BSHRI, Banner Sun Health Research Institute; CCCVD, Cognitive Change in Cerebrovascular Disease; CC75C, Cambridge City over-75's Cohort; CWRU, Case Western Reserve University; FHS, Framingham Heart Study; HAAS, Honolulu-Asia Aging Study; LLDS, Lund Longitudinal Dementia Study; LPRI, Leningrad Psychoneurological Research Institute; MRC CFAS, Medical Research Council Cognitive Function and Ageing Study; NACC, National Alzheimer's Coordinating Center; OP-TIMA, Oxford Project to Investigate Memory and Ageing; PLA, People Liberation Army; ROS, Religious Orders Study; SWBB, South Western Brain Bank; UCI ADRC, University of California at Irvine Alzheimer's Disease Research Center; UCLA, University of California Los Angeles; UMLS CNHOA, University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age; UMMC, University Malaya Medical Centre; AD, Alzheimer disease; CAA, cerebral amyloid angiopathy; CASI, cognitive abilities screening instrument; CDR, clinical dementia rating; CDR-SOB, clinical dementia rating-sum of boxes; CERAD, consortium to establish a registry for Alzheimer's disease; CNS, central nervous system; ICH, intracerebral hemorrhage; IHC, immunohistochemistry; MC, medical center; NR, not reported; QA, total score of quality assessment; UK, United Kingdom; USA, United States of America; WMH, white matter hyperintensity.

*Median age and/or age range were reported instead of mean age (SD).